Lantheus (LNTH) Proxy filing summary

Executive summary

• Curium and Lantheus have entered into a definitive merger agreement, with Curium acquiring all outstanding shares of Lantheus for $102.50 per share in cash, plus up to $12.00 per share in Contingent Value Rights (CVRs) tied to commercial milestones, for a total potential value of $114.50 per share and an aggregate transaction value of up to $8.0 billion.

• The transaction represents a premium of 38% to Lantheus' unaffected 60-day VWAP and is expected to close in the first half of 2027, subject to shareholder and regulatory approvals.

• The combined company will serve oncology, neurology, and cardiology patients in over 70 countries, leveraging complementary strengths in radiodiagnostics and theranostics.

• Lantheus will continue to operate independently until closing, after which it will cease to be publicly traded.

Voting matters and shareholder proposals

• Shareholders will vote on the proposed acquisition at a special meeting, with proxy materials to be distributed in advance.

• The Board of Directors unanimously approved the transaction after a comprehensive review of strategic alternatives.

Board of directors and corporate governance

• The Board conducted a thorough evaluation of strategic options, including outreach to multiple third parties and the option to remain standalone.

• The Board determined the merger to be the value-maximizing path for shareholders.